Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hartemink

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|June 10, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismJohn Hartemink, Kathrine Parker, Sandip Mitra
Glomerular Diseases|December 6, 2023
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic ComplicationsThomas McDonnell, John Hartemink, Omar Ragy, et al.
Nephron|March 11, 2026
A Service Evaluation of Anti-Xa Measurements in Patients with Kidney Impairment in A Tertiary CentreGerard Gurumurthy, Robyn Haysom, Mikias Lemma, et al.
Journal of Nephrology|August 25, 2022
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney diseaseKathrine Parker, John Hartemink, Ananya Saha, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|June 10, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismJohn Hartemink, Kathrine Parker, Sandip Mitra
Glomerular Diseases|December 6, 2023
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic ComplicationsThomas McDonnell, John Hartemink, Omar Ragy, et al.
Nephron|March 11, 2026
A Service Evaluation of Anti-Xa Measurements in Patients with Kidney Impairment in A Tertiary CentreGerard Gurumurthy, Robyn Haysom, Mikias Lemma, et al.
Journal of Nephrology|August 25, 2022
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney diseaseKathrine Parker, John Hartemink, Ananya Saha, et al.
Pageof 1